Pharma MAR SRL
3.9 FTEThe score of Pharma MAR shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +6 % Total assets -50 % Headcount (avg FTE) -35 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharma MAR's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 8,208 € | ||||
| Equity | 223,426 € | ||||
| Cash | 103,374 € | ||||
| EBITDA | 23,251 € | ||||
| Total assets | 492,662 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 Mar 2026
- Year ended 31 Dec 2024filed on 06 Jun 2025
- Year ended 31 Dec 2023filed on 14 Jun 2024
- Year ended 31 Dec 2022filed on 06 Jul 2023
- Year ended 31 Dec 2021filed on 20 Jul 2022
Pharma MAR's financial analysis
- Solvency45.4%sector median: 52.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharma MAR
Pharma MAR's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0634.863.713
- VAT number
- BE0634863713
- Peppol
- Registered · 0208:0634863713 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 05 Aug 2015
- Registered office
- 1000 Brussels
- Size
- Micro · 3.9 FTE
- Latest accounts
- 2025 · filed on 20 Mar 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Pharma MAR (SRL) has been based in Brussels since 2015, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net profit of 8,208 € and equity of 223,426 €; its revenue is not published. With 3.9 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 45.4%, below the median of its sector (52.1%).
Companies similar to Pharma MAR
Companies in the same business, of comparable size and area, outside its group.
- RTLC Manufacture of pharmaceutical preparations Brussels · balance sheet 107,167 €
- Medipharm Worldwide Group Manufacture of basic pharmaceutical products Tienen · balance sheet 331,081 €
- Oropharma Manufacture of pharmaceutical preparations Deinze · balance sheet 352,437 €
- AdipoPharma Belgique Manufacture of pharmaceutical preparations Charleroi · balance sheet 398,195 €
- Laboratoires Sopreli Manufacture of pharmaceutical preparations Anderlecht · balance sheet €1.10m
- Wandji Pharma International Manufacture of pharmaceutical preparations Tournai · balance sheet 357,118 €
- BelCoPhar Manufacture of pharmaceutical preparations Kalmthout · balance sheet 224,468 €
- SpectronRx Europe Manufacture of basic pharmaceutical products Grimbergen · balance sheet 198,933 €
Frequently asked questions about Pharma MAR
What is the revenue of Pharma MAR?
Pharma MAR files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharma MAR?
In Belgium, the VAT number is the company number prefixed with BE: BE0634863713 for Pharma MAR, if the company is VAT-registered. Its company number (CBE) is 0634.863.713.
Where is the registered office of Pharma MAR?
According to the CBE register, the registered office of Pharma MAR is in 1000 Brussels.
What is the equity of Pharma MAR?
At the close of the 2025 financial year, the equity of Pharma MAR amounts to 223,426 €, a solvency of 45.4% of total assets.
How many people work at Pharma MAR?
3.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharma MAR?
The register lists 2 active mandates at Pharma MAR. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharma MAR
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →